These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34299405)

  • 21. (Dipyrido[3,2-a:2',3'-c]phenazine)(glycinato)copper(II) perchlorate: a novel DNA-intercalator with anti-proliferative activity against thyroid cancer cell lines.
    Terenzi A; Tomasello L; Spinello A; Bruno G; Giordano C; Barone G
    J Inorg Biochem; 2012 Dec; 117():103-10. PubMed ID: 23085589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action.
    Verborg W; Thomas H; Bissett D; Waterfall J; Steiner J; Cooper M; Rankin EM
    Br J Cancer; 2007 Oct; 97(7):844-50. PubMed ID: 17848959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metal complexes as DNA intercalators.
    Liu HK; Sadler PJ
    Acc Chem Res; 2011 May; 44(5):349-59. PubMed ID: 21446672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fused aryl-phenazines: scaffold for the development of bioactive molecules.
    Moorthy NS; Pratheepa V; Ramos MJ; Vasconcelos V; Fernandes PA
    Curr Drug Targets; 2014; 15(7):681-8. PubMed ID: 24499398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent development in [1,4]benzodiazepines as potent anticancer agents: a review.
    Gill RK; Kaushik SO; Chugh J; Bansal S; Shah A; Bariwal J
    Mini Rev Med Chem; 2014; 14(3):229-56. PubMed ID: 25311001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of drug binding to DNA by partial intercalation using a model phenazine derivative.
    Kleinwächter V; Balcarová Z; Reinert KE; Triebel H; Grezes JR; Bär H
    Gen Physiol Biophys; 1986 Aug; 5(4):423-32. PubMed ID: 3770461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
    Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification of anticancer drug-induced DNA damage and apoptosis by DNA-binding compounds.
    Kawanishi S; Hiraku Y
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):415-9. PubMed ID: 15379695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectroscopic investigation on the interaction of NCA0424, a potent antitumor indoloquinoxaline derivative, with DNA.
    Ishida T; Mihara Y; Hama Y; Hanatani A; Tarui M; Doi M; Nakaike S; Kitamura K
    Chem Pharm Bull (Tokyo); 1998 May; 46(5):739-43. PubMed ID: 9621408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isoxazolidinyl polycyclic aromatic hydrocarbons as DNA-intercalating antitumor agents.
    Rescifina A; Chiacchio U; Corsaro A; Piperno A; Romeo R
    Eur J Med Chem; 2011 Jan; 46(1):129-36. PubMed ID: 21093966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA intercalator korkormicin A preferentially kills tumor cells expressing wild type p53.
    Kitagaki J; Yang Y
    Biochem Biophys Res Commun; 2011 Oct; 414(1):186-91. PubMed ID: 21946062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis.
    Wheate NJ; Brodie CR; Collins JG; Kemp S; Aldrich-Wright JR
    Mini Rev Med Chem; 2007 Jun; 7(6):627-48. PubMed ID: 17584161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
    Ruiz J; Vicente C; de Haro C; Bautista D
    Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.
    Jobson AG; Willmore E; Tilby MJ; Mistry P; Charlton P; Austin CA
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):889-901. PubMed ID: 18679685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work.
    Martínez R; Chacón-García L
    Curr Med Chem; 2005; 12(2):127-51. PubMed ID: 15638732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA binding to guide the development of tetrahydroindeno[1,2-b]pyrido[4,3,2-de]quinoline derivatives as cytotoxic agents.
    Catoen-Chackal S; Facompré M; Houssin R; Pommery N; Goossens JF; Colson P; Bailly C; Hénichart JP
    J Med Chem; 2004 Jul; 47(14):3665-73. PubMed ID: 15214793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action.
    Palchaudhuri R; Hergenrother PJ
    Curr Opin Biotechnol; 2007 Dec; 18(6):497-503. PubMed ID: 17988854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, DNA-binding and cytotoxicity evaluation of new potential combilexines.
    Hotzel C; Marotto A; Pindur U
    Eur J Med Chem; 2002 May; 37(5):367-78. PubMed ID: 12008051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
    Gamage SA; Spicer JA; Finlay GJ; Stewart AJ; Charlton P; Baguley BC; Denny WA
    J Med Chem; 2001 Apr; 44(9):1407-15. PubMed ID: 11311063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.